Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common antiplatelet drug replace warfarin after APS-Related stroke?

NCT ID NCT05995600

Prevention Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Antiphospholipid syndrome (APS) raises the risk of blood clots and strokes, and doctors often prescribe warfarin to prevent another stroke. Warfarin requires frequent blood tests and carries bleeding risks, especially for younger patients. This trial compares clopidogrel-based antiplatelet therapy with warfarin in adults who have APS and a history of ischemic stroke. Researchers randomly assign participants to one of the two treatments and track deaths, cardiovascular events, blood clots, and major bleeding for at least four years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
clopidogrel-based antiplatelet therapy compared with warfarin
What this could lead to
If clopidogrel works as well as warfarin, people with APS-related stroke could avoid regular blood tests and bleeding risks tied to warfarin.
What could go wrong
The trial is small and exploratory, so it may not settle which drug is better. Clopidogrel can still cause bleeding, and some patients may need warfarin regardless.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 19 years or older * History of ischemic stroke (cerebral infarction, transient ischemic attack, or retinal arterial ischemic event) * Patients who meet the laboratory diagnostic criteria for antiphospholipid syndrome (APS) * Patients or guardians who agree to the study protocol and sign with informed consent Exclusion Criteria: * Patients with high-risk antiphospholipid antibody profile (triple positivity; persistent high-titers exceeding 80 U/mL of anti-cardiolipin or anti-β2 glycoprotein I antibodies) * Systemic lupus erythematous * Patients unable to discontinue previously taken anticoagulants or antiplatelet agents (e.g., atrial fibrillation, valvular heart disease, or a history of percutaneous coronary intervention) * Women who are pregnant, breastfeeding, or intending to become pregnant during the study period * Deemed unsuitable for participation in the study for more than four years, as per the investigators' discretion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antiphospholipid syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

antiphospholipid syndrome cardiovascular disorder cerebrovascular disorder ischemic stroke thrombotic disease transient ischemic attack

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antiphospholipid syndrome Cardiovascular diseases Cerebrovascular disease Ischemic stroke Major bleed Transient ischemic attack

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, South Korea

  • Busan Paik Hospital

    Busan, South Korea

  • Chonnam National University Hospital

    Gwangju, South Korea

  • Chosun University Hospital

    Gwangju, South Korea

  • Chung-Ang University Hospital

    Seoul, South Korea

  • Chungbuk National University Hospital

    Cheongju-si, South Korea

  • Chungnam National University Hospital

    Daejeon, South Korea

  • Chungnam National University Sejong Hospital

    Sejong, South Korea

  • Ewha Woman University Seoul Hospital

    Seoul, South Korea

  • Ewha Womans University Mokdong Hospital

    Seoul, South Korea

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Hallym University Chuncheon Sacred Heart Hospital

    Chuncheon, South Korea

  • Hallym University Kangdong Sacred Heart Hospital

    Seoul, South Korea

  • Hallym University Sacred Heart Hospital

    Anyang, South Korea

  • Hanyang University Guri Hospital

    Guri-si, South Korea

  • Hanyang University Seoul Hospital

    Seoul, South Korea

  • Inha University Hospital

    Incheon, South Korea

  • Jeju National University Hospital

    Jeju City, South Korea

  • Jeonbuk National University Hospital

    Jeonju, South Korea

  • Kangwon National University Hospital

    Chuncheon, South Korea

  • Keimyung University Dongsan Medical Center

    Daegu, South Korea

  • Konkuk University Medical Center

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Kyung Hee University Medical Center

    Seoul, South Korea

  • Pusan National University Hospital

    Busan, South Korea

  • Seoul Metropolitan Government-Seoul National University Boramae Medical Center

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Seongnam, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital

    Seoul, South Korea

  • Uijeongbu Eulji Medical Center

    Uijeongbu-si, South Korea

  • Yeungnam University Medical Center

    Daegu, South Korea

  • Yongin Severance Hospital

    Yongin, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.